Evonik increases prices for EUDRAGIT® and RESOMER® polymers
Evonik Industries will implement price increases for its pharmaceutical excipients and medical device polymers sold under the EUDRAGIT® and RESOMER® brands. The increase is expected to be up to 10% and will become effective on January 1, 2014.
This price increase is necessary to cover cost increases and to maintain the high level of service and quality Evonik customers are accustomed to.
Evonik is committed to continuously investing to enhance the quality and availability of supplies and services and create competitive advantages for its customers. The recent expansion of the global lab and manufacturing resources exemplifies this commitment.
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion (excluding Real Estate).
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.